AIMZ Investment Advisors LLC Reduces Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

AIMZ Investment Advisors LLC trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 226,574 shares of the company’s stock after selling 1,050 shares during the quarter. Teva Pharmaceutical Industries makes up about 1.7% of AIMZ Investment Advisors LLC’s investment portfolio, making the stock its 14th largest holding. AIMZ Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $4,994,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TEVA. Smithfield Trust Co lifted its position in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Venturi Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $60,000. Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $66,000. Finally, Farther Finance Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 273.5% in the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock worth $82,000 after purchasing an additional 3,323 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TEVA shares. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.32 on Friday. The stock has a market capitalization of $18.49 billion, a PE ratio of -11.26, a P/E/G ratio of 1.44 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The business has a 50 day simple moving average of $19.75 and a two-hundred day simple moving average of $18.48. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.